Roche’s Phase III trial of melanoma combination therapy meets primary endpoint
The Phase III trial met its primary endpoint and showed that the combination therapy helped these patients live significantly longer without their disease worsening (progression-free survival; PFS) compared
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.